Formycon integrates AI and digital solutions to enhance biosimilar development efficiency

Formycon AG is incorporating AI and digital technologies into its biosimilar development processes, aiming to optimize workflows and create sustainable value. The company is implementing PhlexTMF Enterprise, an electronic trial master file solution with AI-assisted capabilities, and an AI-powered software for analyzing manufacturing process data.